Shopping Cart

Your shopping cart is currently empty

Fusidic acid sodium salt

Name: Fusidic acid sodium salt
Brand: TargetMol
SKU: T1289
Price: 30 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T1289Cas No. 751-94-0

Alias SQ-16360, Sodium fusidate, Fusidate Sodium, Fucidin

Fusidic acid sodium salt (SQ-16360) is a sodium salt form of fusidic acid, a bacteriostatic antibiotic derived from the fungus Fusidium coccineum and used as a topical medication to treat skin infections.

Fusidic acid sodium salt

Copy Product Info

🥰Excellent

Purity: 99.84%

Catalog No. T1289Alias SQ-16360, Sodium fusidate, Fusidate Sodium, FucidinCas No. 751-94-0

Pack Size	Price	USA Warehouse	Global Warehouse
50 mg	$30	In Stock	In Stock
100 mg	$40	In Stock	In Stock
500 mg	$89	In Stock	In Stock
1 g	$127	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$44	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.84%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Fusidic acid sodium salt (SQ-16360) is a sodium salt form of fusidic acid, a bacteriostatic antibiotic derived from the fungus Fusidium coccineum and used as a topical medication to treat skin infections.
In vivo	Fusidin(Fusidate Sodium) ameliorates EAM, at least partly, through an inhibitory action on the secretion of TNF-a[1]. It markedly attenuates clinical and histological signs of immunoinflammatory diabetes mellitus in mice given streptozotocin(SZ). The effect is dose-dependent, observed in three different strains of mice. Thus, fusidin might have an antidiabetogenic effect[2].
Kinase Assay	Binding assays: Binding assays are performed as previously described (Allenby et al., 1993, 1994). Briefly, labeled and unlabeled retinoids are added to nucleosol or cytosolic fractions in ethanol so that the total amount of ethanol added is constant in all tubes and did not exceed 2% of the incubation volume. The receptor preparations are incubated with retinoids at 4°C for 4–6 hr. Sephadex PD-10 desalting columns are used to separate bound radioligand from free radioligand after equilib- rium is achieved. For competitive binding assays, varying concentrations of unlabeled competing ligand are incubated with the appropriate nucleosol or cytosol in the presence of a fixed concentration of [3H]tRA (sp. act. 49.3 Ci/mmol) or [3H]9-cis RA (sp. act. 24.0 Ci/mmol). Final concentrations of [3H] tRA and [3H]9-cis RA for nuclear receptor binding assays are 5 nM. Final concentrations of [3H] tRA for CRABP binding assays is 30 nM. The IC50s are calculated as described above (DeLean et al., 1978). For saturation kinetics, increasing concentrations of radiolabeled ligand ([3H]tRA sp. act. 49.3 Ci/mmol, [3H]TTNPB sp. act. 5.5 Ci/ mmol) are added to the nucleosol of the appropriate receptor subtype in the presence (nonspecific binding) or absence (total binding) of a 100-fold molar excess of the corresponding unlabeled retinoid. Specific binding is defined as the total binding minus nonspecific binding. Saturation kinetics are calculated as previously described (Scatchard, 1949; Grippo and Gudas, 1987; Levin et al., 1992).
Synonyms	SQ-16360, Sodium fusidate, Fusidate Sodium, Fucidin

Chemical Properties

Molecular Weight	538.69
Formula	C₃₁H₄₇NaO₆
Cas No.	751-94-0
Smiles	[C@]12([C@@]3([C@H](/C(=C(\CCC=C(C)C)/C(=O)[O-])/[C@H](C3)OC(=O)C)C[C@H]([C@H]1[C@@]1([C@@H](CC2)[C@@H]([C@@H](CC1)O)C)C)O)C)C.[Na+]
Relative Density.	no data available

Storage & Solubility Information

Storage

In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 93 mg/mL (172.64 mM), Sonication is recommended.

H2O: 92 mg/mL (170.78 mM), Sonication is recommended.

DMSO: 93 mg/mL (172.64 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.13 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

H2O/Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	1.8564 mL	9.2818 mL	18.5636 mL	92.8178 mL
5 mM	0.3713 mL	1.8564 mL	3.7127 mL	18.5636 mL
10 mM	0.1856 mL	0.9282 mL	1.8564 mL	9.2818 mL
20 mM	0.0928 mL	0.4641 mL	0.9282 mL	4.6409 mL
50 mM	0.0371 mL	0.1856 mL	0.3713 mL	1.8564 mL
100 mM	0.0186 mL	0.0928 mL	0.1856 mL	0.9282 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc